Capricor Therapeutics, Inc. (NASDAQ:CAPR) today announced that a pre-specified administrative interim analysis performed on six-month follow-up data from the ALLSTAR Trial, an ongoing randomized, double-blind, placebo-controlled, 142-patient Phase II clinical trial of CAP-1002 (allogeneic cardiosphere-derived cells) in adults who have experienced a large heart attack with residual cardiac dysfunction, has demonstrated a low probability (futility) of achieving a statistically-significant difference in the 12-month primary efficacy endpoint of percent change from baseline infarct size as a percent of left ventricular mass, measured by cardiac magnetic resonance imaging (MRI). Capricor will continue to perform analyses of the cumulative ALLSTAR data to better understand the basis for this outcome. At six months, a near-statistically-significant (p=0.05) reduction of mean end-diastolic volume, as well as a trend of reduction of mean end-systolic volume, were seen in the CAP-1002 treatment group. There was no notable difference between treatment groups with respect to the change in ejection fraction. There were no safety signals in the CAP-1002 treatment cohort.
Capricor Therapeutics Inc. (NASDAQ: CAPR)’s sales grew -0.01% in the most recent quarter to mrq 906,930%, yielding EPS of $(0.21).
The company generated $(4.58M) in net cash from operations in the latest quarter, bringing its balance at the end of the quarter to 4.55M%. The net change in cash balance from the prior period was $(14.07M).
Let’s look into the charts of the stock
The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend. The market is in highly oversold territory. Beware of a trend reversal.
With that, Capricor Therapeutics Inc. reported $18.75M in total assets at the end of the quarter.
In the current quarter, analysts are looking for EPS of $-0.18 from Capricor Therapeutics Inc.. That compares with EPS of $(0.21) in the last quarter.
Still on the matter of earnings, the company posted EPS of $-1.02 in the last financial year, and EPS for the current year is expected to grow -25.40%% over the prior year.
EPS metric is influenced by profits a company generates in a given period and the number of outstanding shares in it has in that period. For the last quarter where EPS was EPS $(0.21), shares outstanding were 21.4M. In that quarter, Capricor Therapeutics Inc. incurred $- in cost of sales, leaving it with gross profit of $- from the sales of 906,930% it generated in the quarter.
Who owns Capricor Therapeutics Inc.? first, of the company’s outstanding shares, 10.32M are free float. The company’s shares sold short are 2.15%, implying a short ratio of 1.39.
As for the ownership, insiders own 14.50% of the company, with that ownership partly being a result of 16.90% insider transactions in the last couple of months. Institutional investor ownership in the stock is 4.60%, stemming from 0.43% institutional transactions in the recent months.
On Wall Street, analysts on the average have a recommendation of Buy on the stock of Capricor Therapeutics Inc..